Search - tctmd.com

Displaying 161 - 180 of 252

Sort: Relevancy | Date

News Conference News TCT 2020

MitraClip Viable in MI Patients With Acute MR, Including Patients in Shock: IREMMI

Michael O'Riordan

October 17, 2020

News Daily News

TAVR Delays During Pandemic’s Peak Led to Hospitalizations, Deaths

Michael O'Riordan

September 30, 2020

News Daily News

VERTIS CV: Ertugliflozin Meets Noninferiority Endpoint but Misses Other Marks

Michael O'Riordan

September 24, 2020

News Conference News ESC 2020

COVID-19 Blamed for Weaker Research Published by Top-Tier Journals in 2020

Michael O'Riordan

September 04, 2020

News Conference News ESC 2020

Revascularization Benefits ISCHEMIA Patients With Mild LV Dysfunction or HF

Michael O'Riordan

August 31, 2020

News Conference News ESC 2020

EXPLORER-HCM: Mavacamten Improves Exercise Capacity and Functional Class

Michael O'Riordan

August 29, 2020

News Conference News ESC 2020

EMPEROR-Reduced: Empagliflozin Cuts Hospitalizations, CV Mortality in HFrEF

Michael O'Riordan

August 28, 2020

News Daily News

‘Message Unchanged,’ Say Researchers of Criticized COVID-19 CMR Study

Michael O'Riordan

August 26, 2020

News Daily News

HF Care Gaps May Stem From Patient-Specific Factors, Canadian Study Finds

Michael O'Riordan

August 13, 2020

News Daily News

New Guidance on Use of Diabetes Drugs for CVD Risk Reduction: ACC Experts

Michael O'Riordan

August 06, 2020

News Daily News

Higher Risk of HF After ACS for Women Previously on Beta-blockers

Michael O'Riordan

July 16, 2020

News Conference News TVT 2020

MitraClip Cuts Death, HF Hospitalization Across NYHA Class: COAPT

Michael O'Riordan

June 21, 2020

News Conference News HRS 2020

Permanent Conduction-System Pacing After TAVR? Don’t ‘Diss the His’

Michael O'Riordan

May 21, 2020

News Daily News

COVID-19, ACE Inhibitors, and ARBs: Multiple Studies Show No Increased Risk

Michael O'Riordan

May 05, 2020

News Daily News

Smoker’s Paradox Debunked: Post-STEMI Outcomes Worse in Cigarette Smokers

Michael O'Riordan

April 15, 2020

News Features

‘Salvage What We Can’: Cardiology Clinical Trials in Turmoil Amid COVID-19

Michael O'Riordan

April 07, 2020

News Conference News ACC 2020

A Win for Vericiguat in High-Risk Chronic HF Patients: VICTORIA

Michael O'Riordan

March 28, 2020

News Daily News

TAVR and Other Advanced CVD Therapies Used Less in Ontario Than NY State

Michael O'Riordan

January 22, 2020

News Features

‘Outrageous’ $225,000 per Year List Price for Tafamidis Draws Outcry

Michael O'Riordan

January 10, 2020

News Daily News

Most Secondary Prevention Patients Are Eligible for Multiple Drugs

Michael O'Riordan

January 03, 2020

Advertisement

MitraClip Viable in MI Patients With Acute MR, Including Patients in Shock: IREMMI

TAVR Delays During Pandemic’s Peak Led to Hospitalizations, Deaths

VERTIS CV: Ertugliflozin Meets Noninferiority Endpoint but Misses Other Marks

COVID-19 Blamed for Weaker Research Published by Top-Tier Journals in 2020

Revascularization Benefits ISCHEMIA Patients With Mild LV Dysfunction or HF

EXPLORER-HCM: Mavacamten Improves Exercise Capacity and Functional Class

EMPEROR-Reduced: Empagliflozin Cuts Hospitalizations, CV Mortality in HFrEF

‘Message Unchanged,’ Say Researchers of Criticized COVID-19 CMR Study

HF Care Gaps May Stem From Patient-Specific Factors, Canadian Study Finds

New Guidance on Use of Diabetes Drugs for CVD Risk Reduction: ACC Experts

Higher Risk of HF After ACS for Women Previously on Beta-blockers

MitraClip Cuts Death, HF Hospitalization Across NYHA Class: COAPT

Permanent Conduction-System Pacing After TAVR? Don’t ‘Diss the His’

COVID-19, ACE Inhibitors, and ARBs: Multiple Studies Show No Increased Risk

Smoker’s Paradox Debunked: Post-STEMI Outcomes Worse in Cigarette Smokers

‘Salvage What We Can’: Cardiology Clinical Trials in Turmoil Amid COVID-19

A Win for Vericiguat in High-Risk Chronic HF Patients: VICTORIA

TAVR and Other Advanced CVD Therapies Used Less in Ontario Than NY State

‘Outrageous’ $225,000 per Year List Price for Tafamidis Draws Outcry

Most Secondary Prevention Patients Are Eligible for Multiple Drugs

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content